Geriatric Syndrome
Late-Life Depression: Screening & Treatment
Late-life depression is common, frequently missed, and highly treatable — yet older adults often present with somatic complaints, cognitive symptoms ('pseudodementia'), or anhedonia rather than classic sadness. Untreated depression worsens medical outcomes, increases suicide risk (highest in older white men), and is independently associated with dementia, falls, and mortality. This guide covers screening with the PHQ-9 or Geriatric Depression Scale (GDS), differentiating depression from dementia and grief, evaluating for medical contributors (hypothyroidism, B12 deficiency, sleep apnea, medications), and a stepwise treatment approach. SSRIs are first-line — sertraline and escitalopram preferred for tolerability and minimal drug interactions; mirtazapine for patients with insomnia and weight loss. Covers Beers-list avoidances (paroxetine, TCAs), when to add psychotherapy, and when to refer to geriatric psychiatry for treatment-resistant depression or suicidal ideation.
Full clinical workflow, red flags, dosing, and documentation below. Subscribe to read the full guide.
Depression
Depression
Screen all adults · Suicide risk assessment · Treatment matched to severity.
Assessment
How to identify in clinic
- PHQ-2 screen first: "Little interest or pleasure?" + "Feeling down or hopeless?"
- If PHQ-2 ≥3 → follow up with PHQ-9
- GDS-15 (Geriatric Depression Scale) — designed for older adults, avoids somatic confounders
- For patients with dementia: Cornell Scale (CSDD) — caregiver-informant based
Atypical presentations in older adults
- Somatic complaints: fatigue, pain, GI symptoms, weight loss
- Cognitive complaints mistaken for dementia ("pseudodementia")
- Irritability and agitation rather than sadness
- Social withdrawal and apathy
- Functional decline without clear medical cause
- Sleep disturbance (insomnia or hypersomnia)
Always assess
- Suicide risk — older men have highest completed suicide rate
- Substance use (alcohol especially)
- Medication causes (beta-blockers, corticosteroids, opioids)
- Hypothyroidism, B12 deficiency, anemia
Management
Non-pharmacologic
- Behavioral activation — structured daily activities
- Problem-solving therapy (PST) — evidence-based for older adults
- CBT adapted for older adults
- Exercise — 30 min moderate activity most days
- Social engagement — reduce isolation
- Address hearing/vision loss contributing to withdrawal
Medications
- SSRIs first-line: sertraline 25–50 mg start, escitalopram 5 mg start
- SNRIs: duloxetine 20–30 mg (useful if concurrent pain)
- Mirtazapine 7.5–15 mg at bedtime if insomnia + poor appetite
- Start low, go slow — therapeutic trial 6–8 weeks minimum
- Check sodium at 2 weeks (SIADH risk with SSRIs)
- If responding, continue 12+ months before considering taper
Avoid in older adults
- TCAs (amitriptyline, nortriptyline) — anticholinergic, cardiac risk
- Paroxetine — most anticholinergic SSRI
- Benzodiazepines for anxiety with depression — fall risk, dependence
Refer & Document
When to refer
- Psychiatry — suicidal ideation, psychotic features, treatment resistance (2+ failed trials)
- Psychology — CBT, PST, or behavioral activation therapy
- Social work — if isolation, caregiver burden, or housing issues
- Emergency — active suicidal plan or intent
Referral should include
- PHQ-9 or GDS score
- Suicide risk assessment result
- Medication trials and outcomes
- Cognitive screening result (to distinguish from dementia)
- Functional impact
Documentation must include
- Validated screening tool and score
- Suicide risk assessment
- Medical workup (TSH, B12, CBC)
- Medication review for depressogenic drugs
- Treatment plan with follow-up timeline
Dangerous Pitfall
Older adults — especially older white men — have the highest completed suicide rate. They are less likely to report suicidal ideation and more likely to use lethal means. Always screen. Always ask directly: "Have you had thoughts of hurting yourself or ending your life?" Do not assume a quiet patient is not at risk.
Evidence sources
- · APA Late-Life Depression Guidelines
- · USPSTF Depression Screening 2023
Review status
Last reviewed: 2026-04
Reviewed by the MyClinicianGuide editorial team. Cadence: annual.
Educational reference for licensed clinicians (NP, PA, MD, DO). Not a substitute for clinical judgment, institutional protocols, or specialty consultation. Apply in context of the full clinical picture, patient goals, and current standards of care. See About AI guidance for AI-related limitations.
Subscribe to read this page
This page is part of the full subscription. You can keep previewing the free sections, or unlock everything for $29.99/month.
- ✓6 hubs and 150+ evidence-cited pages on older adults, geriatric syndromes & urgent care
- ✓Urgent Care survival guide, syndromes, vague-symptom workups, medications
- ✓AI Guide + interactive tools
- ✓7-day money-back guarantee on your first purchase
- ✓Cancel anytime — no contract; access continues to the end of your billing period